Keyword: benralizumab

AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to its cancer drugs—and once again, China.

England's cost watchdog has removed a previous restriction on AZ's Fasenra, allowing it to be funded for an expanded pool of patients.

A lot has changed in the severe asthma market lately—including the way GlaxoSmithKline is talking about its contender, Nucala.

AZ struck out in May in trying to expand Fasenra into COPD. But it does have new long-term data that could bolster the drug in its current indication.

AstraZeneca's CEO knows he keeps saying the same thing, but once again, he had just one message for investors Thursday: Hang in there.

AstraZeneca's Fasenra hasn't had an easy time challenging GlaxoSmithKline’s Nucala. And doing so just got harder close to home.

AstraZeneca’s hopes for expanding severe asthma drug Fasenra into COPD are officially lost.

AZ was hoping its next-gen COPD med Fasenra could help it keep pace with GlaxoSmithKline, but the drug just failed to beat placebo in a phase 3 study.

Teva was hoping to level the convenience playing field in severe asthma with a subcutaneous version of Cinqair. But those plans have hit a snag.

GlaxoSmithKline may have some new Nucala competition in severe asthma, but it also has a new market all to itself.